Page last updated: 2024-08-05 11:05:25
adamantanes
Compounds containing an adamantane skeleton.
ChEBI ID: 51339
Members (7)
| Member | Definition | Role |
|---|---|---|
| a 77636 | An isochromene that is 3,4-dihydroisochromene-5,6-diol bearing additional aminomethyl and 1-adamantyl substituents at positions 1 and 3 respectively (the 1R,3S-diastereomer). Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo. | (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol |
| adamantane | adamantane | |
| adapalene | A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether. | adapalene |
| amantadine | A member of the class of adamantanes that is used as an antiviral and antiparkinson drug. | amantadine |
| bms 477118 | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-amino(3-hydroxyadamantan-1-yl)acetic acid with the amino group of (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile. Used in its monohydrate form for the treatment of Type II diabetes. | saxagliptin |
| cd 437 | A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells. | CD437 |
| memantine | A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | memantine |
Research
Studies (9,843)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1,784 (18.12) | 18.7374 |
| 1990's | 990 (10.06) | 18.2507 |
| 2000's | 2,550 (25.91) | 29.6817 |
| 2010's | 3,635 (36.93) | 24.3611 |
| 2020's | 884 (8.98) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,366 (12.52%) | 5.53% |
| Reviews | 1,475 (13.52%) | 6.00% |
| Case Studies | 584 (5.35%) | 4.05% |
| Observational | 51 (0.47%) | 0.25% |
| Other | 7,431 (68.13%) | 84.16% |